Teva Pharmaceutical Industries Ltd. TEVA
39.19
(1.03)
(2.56%)
as of 25 Sep
- Market cap
- $46.9B
- P/E
- 62.2×
Follow TEVA
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
10.44% | 21.21% | 21.58% | 9.69% | |
| 1.74% | 3.52% | 3.99% | 1.77% | ||
ROIC |
7.84% | 6.37% | 6.77% | 4.58% | |
Return on Tangible Assets |
11.74% | 30.85% | 37.48% | 34.62% | |
Average Days of Receivables |
82.90 | 78.44 | 71.38 | 73.63 | |
Free Cash Flow per Share |
0.54 | 1.03 | 1.06 | 1.20 | |
Free Cash Flow |
616.00 | 1,182.00 | 1,231.00 | 1,401.00 | |
Capital Expenditures |
(450.00) | (467.00) | (483.00) | (497.00) | |
Piotroski F-Score |
8.00 | 8.00 | 7.00 | 7.00 | |
| Other line items | |||||
Cash ROIC |
4.06% | 5.83% | 5.99% | 6.78% | |
Accounts Receivable Turnover |
4.61 | 5.10 | 5.12 | 4.91 | |
Accounts Payable Turnover |
3.54 | 3.52 | 3.40 | 3.15 | |
Inventory Turnover |
2.30 | 2.69 | 2.59 | 2.45 | |
Average Days of Payables |
102.65 | 111.04 | 113.93 | 120.65 | |
Days of Inventory on Hand |
144.84 | 139.46 | 139.38 | 142.82 | |
Tax Rate |
(0.27) | 0.15 | 0.14 | (0.02) | |
Research and Development Expense of Revenue |
5.93% | 5.87% | 5.69% | 9.90% | |
Selling, General and Administrative Expense of Revenue |
22.68% | 23.02% | 23.37% | 23.85% | |
Share Based Compensation of Revenue |
0.83% | 0.91% | 0.96% | 0.97% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.50 | 1.17 | 1.10 | 2.68 | |
Depreciation/Fixed assets |
0.21 | 0.25 | 0.25 | 0.25 | |
Capex/Depreciation |
(0.45) | (0.47) | (0.48) | (0.50) | |
Revenue per Share |
14.63 | 15.07 | 15.01 | 14.86 | |
Operating CF per Share |
0.93 | 1.44 | 1.48 | 1.63 | |
Capex per Share |
(0.39) | (0.41) | (0.42) | (0.43) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
4.24% | 8.17% | 9.02% | 4.08% |
Columns are period end dates